Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2014.03.017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Allogeneic Stem Cell Transplantation as Treatment for Myelofibrosis

Bone Marrow Transplantation
TransplantationHematology
2006English

Serial 18f-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Therapeutic Potential of Janus-Activated Kinase-2 Inhibitors for the Management of Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2010English

Diagnostic Value of 18f-FDG-Pet/Ct for Monitoring Myelofibrosis After Allogeneic Stem Cell Transplantation

Nuclear Medicine Review
MedicineNuclear MedicineRadiologyImaging
2015English

Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Allogeneic Stem Cell Transplantation for Sickle Cell Disease

Current Opinion in Hematology
Hematology
2016English

Cytokine Expression Pattern in Bone Marrow Microenvironment After Allogeneic Stem Cell Transplantation in Primary Myelofibrosis

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Allogeneic Hematopoietic Stem Cell Transplantation

Archives of Internal Medicine
2002English

The Microbiome and Allogeneic Stem Cell Transplantation

Current Stem Cell Reports
GeneticsDevelopmental BiologyCell BiologyMolecular Biology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy